Bevacizumab, a humanized monoclonal antibody against VEGF, has been utilized in combination with chemotherapy as a first-line treatment for metastatic CRC, thereby demonstrating significant benefits for patients (Ferrara et al., 2004). The gene discussed is VEGFA; the disease is colorectal carcinoma.